• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Thestreet.com

Thestreet.com

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Tesaro's new ovarian drug will cost cancer patients $60,000 to $177,000 a year

    Tesaro's new ovarian drug will cost cancer patients $60,000 to $177,000 a year

  2. UPDATE: Tesaro drug pricing snafu sends stock down 3% and lifts rival drugmaker's shares

    UPDATE: Tesaro drug pricing snafu sends stock down 3% and lifts rival drugmaker's shares

  3. UPDATE: Tesaro stock dives 7% after drug pricing snafu

    UPDATE: Tesaro stock dives 7% after drug pricing snafu

  4. UPDATE: This is the next big catalyst for Amazon's stock (and it's not the NFL)

    UPDATE: This is the next big catalyst for Amazon's stock (and it's not the NFL)

  5. This is the next big catalyst for Amazon's stock (and it's not the NFL)

    This is the next big catalyst for Amazon's stock (and it's not the NFL)

  6. Leafbuyer Goes Public

    Leafbuyer Goes Public

  7. Shopping Malls: Goners?

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

  8. Advisor Profile: Best of Both Worlds

    Two advisors take different approaches in their portfolios to achieve the same goals: low risk and stability.

12

©2017 Morningstar Advisor. All right reserved.